Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Rheumatoid Arthritis

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Ann Rheum Dis.

Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T

doi: 10.1136/annrheumdis-

Spinal Disorders

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

Rheumatology (Oxford).

Baraliakos X, Witte T, De Clerck L, Frediani B, Collantes-Estévez E, Katsifis G, VanLunen B, Kleine E, Hoepken B, Bauer L, Goodson N

doi: 10.1093/rheumatology/keaa181.

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Rheumatology (Oxford).

van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A

doi: 10.1093/rheumatology/kex174.

Rheumatoid Arthritis

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Ann Rheum Dis.

Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME

doi: 10.1136/

Spinal Disorders

Tumour necrosis factor inhibitor dose reduction for axial spondyloarthritis: A systematic review and meta-analysis of randomized controlled trials

Arthritis Care Res (Hoboken).

Lawson DO, Eraso M, Mbuagbaw L, Joanes M, Aves T, Leenus A, Omar A, Inman RD

doi: 10.1002/acr.24184.

Spinal Disorders

A 52-Week Randomized Placebo-Controlled Trial of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis

Arthritis Rheumatol.

Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D

doi: 10.1002/art.40866.

Further Publications Rheumatology

How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort

Rheumatology (Oxford)

Nikiphorou E, Boonen A, Fautrel B, Richette P, Landewé R, van der Heijde D, Ramiro S

doi: 10.1093/rheumatology/keab607

Further Publications Rheumatology

Tapering of TNF inhibitors in axial spondyloarthritis in routine care-2-year clinical and MRI outcomes and predictors of successful tapering

Rheumatology (Oxford)

Wetterslev M, Georgiadis S, Juul Sørensen I, Juhl Pedersen S, Christiansen SN, Hetland ML, Brahe CH, Bakkegaard M, Duer A, Boesen M, Gosvig KK, Møller JM, Krogh NS, Jensen B, Madsen OR, Christensen J, Hansen A, Nørregaard J, Røgind H, Østergaard M

doi: 10.1093/rheumatology/keab755

Further Publications Rheumatology

Factors associated with remission at 5-year follow-up in recent onset axial spondyloarthritis: results from the DESIR cohort

Rheumatology (Oxford)

Pina Vegas L, Sbidian E, Wendling D, Goupille P, Ferkal S, Le Corvoisier P, Ghaleh B, Luciani A, Claudepierre P

doi: 10.1093/rheumatology/keab565

Related content

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Tumour necrosis factor inhibitor dose reduction for axial spondyloarthritis: A systematic review and meta-analysis of randomized controlled trials

A 52-Week Randomized Placebo-Controlled Trial of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis

How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort

Tapering of TNF inhibitors in axial spondyloarthritis in routine care-2-year clinical and MRI outcomes and predictors of successful tapering

Factors associated with remission at 5-year follow-up in recent onset axial spondyloarthritis: results from the DESIR cohort